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Abstract
Background: Extra-pulmonary tuberculosis (EPTB) represents about 14% of all cases of tuberculosis (TB) in Malaysia.
The aims of the study include evaluation of socio-demographic factors, clinical manifestations, co-morbidities
among patients with EPTB and their treatment outcomes.
Methods: A retrospective study was conducted to recognize the epidemiology facts of EPTB. Individual data for
EPTB patients were collected from TB registers, laboratory TB registers, treatment cards and TB medical personal
files into a standardized study questionnaire. Crude (COR) and adjusted odds ratios (AOR) and 95% confidence
intervals (CI) were determined to assess the risk factors for EPTB and unsuccessful treatment outcomes.
Results: There were 1222 EPTB patients presenting 13.1% of all TB cases during 2006–2008. Pleural effusion and
lymph node TB were the most frequent types and accounted for 45.1% of all EPTB cases among study participants.
Treatment success rate was 67.6%. The best treatment completion rates were found in children ≤15 years (0.478
[0.231–1.028]; p = 0.05). On multivariate analysis, age group 56–65 years (1.658 [1.157–2.376]; p = 0.006), relapse
cases (7.078 [1.585–31.613]; p = 0.010), EPTB-DM (1.773 [1.165–2.698]; p = 0.008), patients with no formal (2.266
[1.254–4.095]; p = 0.001) and secondary level of education (1.889 [1.085–3.288]; p = 0.025) were recorded as
statistically positive significant risk factors for unsuccessful treatment outcomes. Patients at the risk of EPTB
were more likely to be females (1.524 [1.311–1.746]; p < 0.001), Malays (1.251 [1.056–1.482]; p = 0.010) and Indians
(1.450 [1.142–1.842]; p = 0.002), TB-HIV (3.215 [2.347–4.405]; p < 0.001), EPDM-HIV (4.361 [1.657–11.474]; p = 0.003), EPTB-
HIV-HEP (4.083 [2.785–5.987]; p < 0.001), those living in urban areas (1.272 [1.109–1.459]; p = 0.001) and no formal
education (1.361 [1.018–1.820]; p = 0.037).
Conclusion: The findings of this study extend the knowledge of EPTB epidemiology and highlight the need
for improved EPTB detection in Malaysia, especially in subpopulations with high risk for EPTB and unsuccessful
treatment outcomes.
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Background
TB is the ninth foremost reason of death worldwide and
the leading cause from a single infectious agent, ranking
above HIV/AIDS [1]. Overall, a relatively small propor-
tion (5–15%) of the people infected with Mycobacterium
tuberculosis (MTB) will develop TB disease during their
lifetime. However, the probability of developing TB
disease is much higher among people infected with HIV,
and also higher among people affected by risk factors
such as under-nutrition, diabetes, smoking and alcohol
consumption [1].
Pulmonary TB (PTB), the most common type of TB,
has the great epidemiological significance due to its
extremely contagious nature [2]. The proportion of
patients with extra-pulmonary TB (EPTB) relative to
those with PTB varies among countries and depends on
associated diseases, geographical, social, ethnic and
economic parameters [3, 4]. EPTB is defined according
to WHO classification criteria as an infection by MTB
which affects tissues and organs outside the pulmonary
parenchyma. It represents between 20 and 25% of all TB
cases [5].
In the early 1940s and 1950s, TB was graded as the
main reason of death in Malaysia. Realizing its serious-
ness, the Malaysian government launched its National
TB Control Program (NTP) in 1961 [6]. With regards to
the type of TB, of 25,739 reported TB cases in Malaysia
during 2016, 22,135 (86%) were PTB cases while 3604
(14%) were EPTB [1]. The most common forms of EPTB
seen in Malaysia are TB lymphadenitis, bone/joint TB
and miliary TB [6]. From 1990 to 2016, the number of
TB-HIV co-infection reported nationwide has increased
from 6 to 3396 cases [7]. EPTB involvement tends to in-
crease in frequency if the immune system is compro-
mised [2]. Diabetes Mellitus (DM) has been identified as
a risk factor for TB [8–10]. Although immune deficiency
also occurs with diabetes, but little is known about the
epidemiological or clinical relationship between diabetes
and EPTB. However, we hypothesized that infectious
and immune-compromised conditions increased frequency
and severity of EPTB. The current study was con-
ducted with the aim to evaluate the clinical character-
istics and treatment outcomes of patients with EPTB.
Furthermore, we were interested to identify the risk
factors of EPTB on socio-demographic, co-morbidities
and clinical basis.
Methods
Study design and data collection
A retrospective study was conducted in four states of
Malaysia from 2006 to 2008. Data on socio-demo-
graphic, clinical, histopathological, microbiological and
other laboratory variables of EPTB cases were collected
from TB registers, treatment cards and TB medical
personal files using standard data collection tool. Pa-
tients in whom the site of infection was confined to
lungs were considered as PTB while infection extended
to other organs or tissues outside lungs were considered
as EPTB. Patients who had both PTB and EPTB involve-
ments were excluded from the analysis of EPTB based
on WHO sample selection policy [11]. The sites of infec-
tion were as lymph nodes, gastrointestinal system,
spinal, meningitis pleural effusion, miliary and bones/
joints. All other sites of infection were considered as
part of a seventh group identified as “other rare forms”
(including urogenital, eyes, ear, breast etc.) for conveni-
ent statistical analysis the diagnosis of EPTB was done
following Clinical Practice Guidelines [12], which is con-
sistent with the WHO’s diagnostic criteria [13]. Treat-
ment success refers to the patients who were cured and
have completed TB treatment. Completed TB treatment
was defined as any patient who had completed a TB re-
gime based on the Clinical Practice Guidelines created
by Malaysia Ministry of Health [12].
Study location
The study was carried out in selected hospitals and
prisons located in four states of Malaysia (Penang,
Sabah, Sarawak, and Selangor). The states of Penang,
Sabah and Sarawak were selected for the present study
based on previous literature report of TB burden. The
prevalence of TB in Malaysia was highest in Sabah
followed by Sarawak and Penang [6]. The state of
Selangor was also considered for the present study as it
has two big prisons at national level in Malaysia.
Data analysis
The whole data collection form was assigned a serial
number to ensure the traceability. Coding of the
responses was carried out and the data was entered into
the computer and analysed by using statistical package
for SPSS for Windows version 16.0 (SPSS, Inc., Chicago,
IL, USA). Logistic regression model was used to analyze
the predictors for EPTB and unsuccessful treatment
outcomes. However, p value was used to calculate sig-
nificance of of co-morbidities among different variables.
Factors found significant in univariate analysis, were
finally included in multivariate logistic regression to
estimate the odds ratios (ORs) with their 95% confidence
intervals (CIs). A p value < 0.05 was considered statisti-
cally significant.
Results
Proportion, socio-demographic and baseline clinical
characteristics
Proportion of EPTB registered in four states of Malaysia
during study time period is shown in Table 1. Patients
with EPTB constituted about 13.1% of all TB cases, with
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higher prevalence in Selangor than other three states.
Socio-demographic and clinical characteristics of pa-
tients are shown in Table 2. The study cohort included
778 (63.7%) males and 444 (36.3%) females. Of the 1222
cases included in the present study, age group 26–35
years constituted the highest cases (24.2%) and least
numbers were recorded for ≤15 years old (4.5%). In
terms of residence, higher proportions of EPTB were
observed in the urban areas (67%). The results showed
that there was a significant difference (p < 0.001) in the
incidence of EPTB among different races. The Malays
seemed to be highly affected with a number of 389
(31.8%) cases followed by the Chinese (23.9%).
Around, 330 (27%) of cases had acid fast bacilli smear
positive and 687 (56.2%) culture positive. However, 360
patients (29.5%) were diagnosed via pathology alone and
43 (3.5%) were confirmed on polymerase chain reaction
(PCR). Among the culture confirmed EPTB cases, 1.5%
of patients were resistant to single first line drugs. On
baseline 4 patients were recorded resistant to isoniazid
and 4 for streptomycin whereas 1 each for rifampicin
and ethambutol. Of HIV co-infection, 139 patients were
receiving Highly Active Antiretroviral Therapy (HAAR
T). For EPTB patients with DM, 152 were getting oral
hypoglycemics, 24 patients were on insulin whereas 6
had oral hypoglycemic agents plus insulin.
Frequency distribution of EPTB
Of 9335 all TB cases registered during the study time
period, 1222 had EPTB. Lymph node 324 (26.5%) and
Pleural effusion 227 (18.6%) TB were the most frequent
types of all EPTB cases among study participants (Table
2). The proportions of different types of EPTB varied
with statistically significant difference observed among
gender (p = 0.03), age groups (p < 0.001), different ethnic
groups (p < 0.001), co-morbidities (p < 0.001), and
smokers (p < 0.001) (Table 2).
EPTB and co-morbidities
Out of 1222 EPTB patients, 525 (43%) were recorded
with co-morbidities. Chi-square analysis of categorical
variables of the study participants showed a significant
difference in males and females, distribution of age,
races, residence, patient categories, marital status, edu-
cation and employment between EPTB and comorbidi-
ties groups (Table 3). Among the co-morbidities, HIV
and DM contributed to the highest cases and almost at
the equal rate. Overall, higher proportions of all comor-
bidities were seen among males than females and
patients aged 35 years or older. Numbers of EPTB with
diabetes mellitus (EPTB-DM), EPTB with human
immunodeficiency virus (EPTB-HIV) and EPTB and
hepatitis (EPTB-HEP) cases were frequently seen among
35–55 years age whereas the co-morbidities became
more complex with increasing age. Patients from the
rural areas were significantly had increased proportions
of HIV related comorbidities. Moreover, patients with
CD4+ lymphocyte cell counts < 100 had 37.3% lymph
node TB, 18.6% cases of miliary and pleural TB each.
We further confirmed that of total deaths among known
CD4+ lymphocyte count, 55% occurred in patients with
< 100 counts. Other diseases which patients already had
at the baseline include hypertension (3%), ischemic heart
disease (1%), renal failure (2%), lung carcinoma (0.2%),
lung fibrosis (0.2%), liver cirrhosis (0.2%), hypertension
and COPD (0.2%), ischemic heart disease+ renal failure+
hypertension (0.4%) (Table 3).
Treatment outcomes
Around, 67.6% (826/1222) patients successfully com-
pleted treatment. Treatment outcomes in relation to
socio-demographic characteristics and co-morbidities
are shown in Table 4. There were no statistically signifi-
cant differences seen with regard to treatment outcomes
among males and females, residency, ethnicity, alcohol
habit and employment on univariate analysis (Table 4).
On multivariate analysis (Table 4), age group 56–65
years (1.658 [1.157–2.376]; p = 0.006), relapse cases
(7.078 [1.585–31.613]; p = 0.010), EPTB-DM (1.773
[1.165–2.698]; p = 0.008), patients with no formal (2.266
[1.254–4.095]; p = 0.001) and secondary level of educa-
tion (1.889 [1.085–3.288]; p = 0.025) were recorded as
statistically positive significant risk factors for unsuccess-
ful treatment outcomes. Comparing the proportion of
default and deaths among different types of EPTB,
significantly higher were reported in meningitis and mil-
iary TB (Fig. 1).
Of 139 patients who were on HAART, 111 (79.9%)
successfully completed the treatment while the remaining
28 (20.1%) had unsuccessful treatment outcomes. Never-
theless, statistically significant association was observed
between DM and treatment outcomes for EPTB-DM
patients. When death and default cases were compared
among the different co-morbidities, maximum death cases
were observed for EPTB-DM-HEP followed by EPTB-
DM-HIV. However, higher proportions of default were
seen among patients with EPTB-DM (Fig. 2).
Table 1 Proportion of PTB and EPTB registered in four states of
Malaysia during 2006–2008
States PTB n (%) EPTB n (%) Total
Penang 1285 (84.8) 230 (15.2) 1515
Sabah 3803 (88.3) 504 (11.7) 4307
Sarawak 1722 (91.5) 160 (8.5) 1882
Selangor 1303 (79.9) 328 (20.1) 1631
Total 8113 1222 9335
PTB Pulmonary TB, EPTB Extra- Pulmonary TB
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Risk factors of EPTB
With EPTB as the case group and PTB as the control
group, we assessed the associations between the vari-
ables and having EPTB based on logistic regression
model. Based on the result of the adjusted odd ratio
(AOR), females appeared to have a higher risk for having
EPTB (1.524 [CI: 1.311–1.746]; p < 0.001) than males
(Table 5). Malays (1.251 [1.056–1.482]; p = 0.010),
Indians (1.450 [1.142–1.842]; p = 0.002), urban residents
(1.272 [1.109–1.459]; p = 0.001), patients with no formal
education (1.361 [1.018–1.820]; p = 0.037), those with
married (1.199 [1.038–1.384]; p = 0.014) and with
unknown marital status (2.757 [1.611–4.717]; p < 0.001)
had significantly higher odds for having EPTB. Among
Fig. 2 Proportion of default and deaths among patients with EPTB and different co-morbidities
Fig. 1 Proportion of default and deaths among different types of EPTB among patients
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Table 5 Logistic regression models to determine independent risk factors for having EPTB
Variables Univariate analysis P-value Multivariate analysis P-value
COR (95% CI) AOR (95% CI)
Gender
Male 0.75 (0.66 to 0.86) < 0.001 0.65 (0.57 to 0.75) < 0.001
Female 1.31 (1.16 to 1.49) 1.52 (1.31 to 1.74)
Age (years)
≤ 15 1.115 (0.78 to 1.58) 0.541
16–25 1.11 (0.95 to 1.31) 0.170
26–35 0.90 (0.77 to 1.05) 0.198 ----------------------- -------
36–45 0.96 (0.82 to 1.12) 0.604
46–55 1.02 (0.87 to 1.20) 0.741
56–65 0.94 (0.79 to 1.13) 0.566
≥ 66 1.06 (0.87 to 1.28) 0.546
Ethnicity
Malay 1.33 (1.16 to 1.51) < 0.001 1.25 (1.05 to 1.48) 0.010
Chinese 1.02 (0.89 to 1.17) 0.740 --------------------- -------
Indian 1.58 (1.28 to 1.94) < 0.001 1.45 (1.14 to 1.84) 0.002
Immigrants Indonesian 0.72 (0.55 to 0.94) 0.018 0.76 (0.56 to 1.02) 0.069
Immigrants Philippines 0.65 (0.47 to 0.89) 0.008 0.77 (0.55 to 1.09) 0.144
Sarawakian 0.61 (0.48 to 0.77) < 0.001 0.76 (0.58 to 0.99) 0.046
Sabahian 0.80 (0.68 to 0.94) 0.009 0.91 (0.74 to 1.12) 0.388
Others 1.63 (1.08 to 2.46) 0.019 1.51 (0.97 to 2.35) 0.064
Residence
Urban 1.17 (1.03 to 1.33) 0.015 1.27 (1.10 to 1.45) 0.001
Rural 0.85 (0.75 to 0.97) 0.78 (0.68 to 0.90)
Patient category
Unknown 0.30 (0.20 to 0.46) < 0.001 0.21 (0.12 to 0.35) < 0.001
New 1.92 (1.53 to 2.40) < 0.001 1.57 (1.20 to 2.05) 0.001
Relapse 0.73 (0.56 to 0.94) 0.017 4.65 (2.80 to 7.73) < 0.001
Co-morbidity
Only TB 0.73 (0.65 to 0.83) < 0.001 0.89 (0.68 to 1.16) 0.406
TB-DM 0.66 (0.56 to 0.78) < 0.001 0.67 (0.50 to 0.91) 0.011
TB-HIV 2.35 (1.97 to 2.80) < 0.001 3.21 (2.34 to 4.40) < 0.001
TB-Hep 0.99 (0.75 to 1.31) 0.990 --------------------- -------
TB-DM-HIV 3.33 (1.34 to 8.27) 0.009 4.36 (1.65 to 11.47) 0.003
TB-DM-Hep 1.30 (0.68 to 2.50) 0.419 ---------------------- -------
TB-HIV-Hep 3.01 (2.30 to 3.95) < 0.001 4.08 (2.78 to 5.98) < 0.001
Smoking habit
Ex-smoker 1.54 (1.28 to 1.84) < 0.001 1.53 (1.26 to 1.87) < 0.001
No 0.96 (0.85 to 1.09) 0.599 ---------------------- -------
Yes 0.85 (0.75 to 0.97) 0.017 0.78 (0.67 to 0.91) 0.001
Drinking Habit
Unknown 0.73 (0.40 to 1.33) 0.314
No 0.95 (0.78 to 1.15) 0.623 ----------------------- -------
Yes 1.10 (0.89 to 1.35) 0.356
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the co-morbid conditions, patients with EPTB-HIV
(3.215 [2.347–4.405]; p < 0.001), EPTB-DM-HIV (4.361
[1.657–11.474]; p = 0.003) and EPTB-HIV-HEP (4.083
[2.785–5.987]; p < 0.001) found to have increased risk of
EPTB.
Discussion
To the best of our knowledge, this is the first study in
Malaysia to describe the epidemiological, clinical charac-
teristics and treatment outcomes among patients with
EPTB and its co-morbidities. Patients with EPTB consti-
tuted 13.1% of all notifications, with some parts of the
country showing higher prevalence than others. There
were important variations in the proportion of EPTB pa-
tients in the different states of the country; and this
could be related to the implication of medical doctors in
the diagnosis of EPTB. The proportion of patients diag-
nosed with EPTB in the present study was lower than
that reported from other parts of world [14–16]. Pre-
dominant sites of EPTB were lymph node followed by
pleural effusion. The higher prevalence of lymph node
and pleural effusion has previously been reported in
Malaysia and other global regions [6, 15, 17, 18]. The
other rare forms included TB of the eye, ear, breast,
neck, skin and spondylitis. Beside this, there were 18
cases who had EPTB at more than one site.
Frequency of different sites of EPTB varied among
co-morbidities. Lymph node and pleural effusion were
observed at higher proportion, followed by miliary
and meningitis TB. Association between HIV and sites
of EPTB has been determined more than a decade
ago [19] however; the data is limited or almost absent
for DM and HEP. Consistent with previous studies
[20, 21] we found advanced HIV strongly correlated
with the occurrence of EPTB. These findings are in
contrast to [22] but are in agreement with [23]. Fur-
thermore, severe immunosuppression like low CD4+
lymphocyte cell counts and advanced HIV infection,
increases the risk of having EPTB as opposed to PTB
alone [24, 25]. Moreover, on comparing CD4+
lymphocyte cell counts with smoking, CD4+ lympho-
cyte cell counts < 100 was significantly recorded for
smokers (p = < 0.05). This is the first study in identify-
ing smoking association with CD4+ lymphocyte cell
counts < 100 among EPTB-HIV. The previous study
by Feldman and companions suggested lower CD4+
lymphocyte cell counts in HIV patients with smoking
habit [26].
Table 5 Logistic regression models to determine independent risk factors for having EPTB (Continued)
Variables Univariate analysis P-value Multivariate analysis P-value
COR (95% CI) AOR (95% CI)
IVDUa
Unknown 1.60 (1.01 to 2.53) 0.044 1.16 (0.67 to 2.01) 0.578
No 0.75 (0.61 to 0.94) 0.012 0.93 (0.71 to 1.22) 0.624
Yes 1.24 (0.98 to 1.58) 0.071 ---------------------- --------
Marital status
Unknown 2.68 (1.63 to 4.42) < 0.001 2.75 (1.61 to 4.71) < 0.001
Married 1.18 (1.03 to 1.34) 0.013 1.19 (1.03 to 1.38) 0.014
Unmarried 0.80 (0.70 to 0.91) 0.001 0.36 (0.21 to 0.62) < 0.001
Education
Unknown 0.87 (0.76 to 0.99) 0.041 0.95 (0.80 to 1.13) 0.603
Primary 0.90 (0.73 to 1.10) 0.319 ---------------------- --------
Secondary 1.23 (0.97 to 1.57) 0.081 ---------------------- --------
College 0.89 (0.64 to 1.24) 0.499 ---------------------- --------
University 1.10 (0.52 to 2.34) 0.790 ---------------------- --------
Diploma 1.43 (0.88 to 2.33) 0.146 ---------------------- --------
No formal education 1.55 (1.21 to 2.00) 0.001 1.36 (1.01 to 1.82) 0.037
Employment status
Unknown 1.17 (0.99 to 1.39) 0.057
Employed 1.06 (0.92 to 1.21) 0.377 ---------------------- --------
Unemployed 0.87 (0.77 to 0.99) 0.033
TB-DM Co-infection of TB and Diabetes Mellitus, TB-HIV Co-infection of TB and HIV, TB-Hep Co-infection of TB and Hepatitis, TB-DM-HIV Co-infection of TB with
Diabetes Mellitus and HIV, TB-DM-Hep Co-infection of TB with Diabetes Mellitus and Hepatitis, TB-HIV-Hep Co-infection of TB with HIV and Hepatitis
aIntravenous Drug Users
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A significant association was observed between co-
morbidities and age, gender, ethnicity, patient category,
education and marital and employment status. Propor-
tions of co-morbidities were greater in males, unmarried
and unemployed patients comparative to their counter-
parts. The results show that the risk of developing co-
morbidities remained higher at the age of 26 years and
older. Of total 1222 patients in the present study, 525
were recorded for different co-morbidities with EPTB-
HIV and EPTB-DM being the most common. Moreover,
11.4% of patients had EPTB-HEP and 15% cases were
seen with EPTB-HIV-HEP co-infection. During last
decade, one case-control study in US demonstrated
association of hepatitis C infection with TB disease [27].
Later on, it was confirmed by further studies showing
that hepatitis C infection and TB share the same high
risks population [28–30]. Very recently study conducted
in Taiwan has reported that hepatitis C infection intensi-
fies the risk of developing TB [31]. The mechanism
behind this finding remains unclear. Future studies in
this perspective are needed.
Treatment success rate in our study was 67.6% (826/
1222). On multivariate analysis, age group 56–65 years,
relapse cases, EPTB-DM, patients with no formal and
secondary level of education were recorded as statisti-
cally positive significant risk factors for unsuccessful
treatment outcomes. Treatment success rate among
patients on HAART was 79.9% which is far better than
that mentioned in a study conducted in Kelantan, north-
east Malaysia [32]. On the other side, EPTB-DM patients
had higher odds for unsuccessful treatment outcomes.
Poor outcomes in patients with DM-TB could be due to
immune deficiency triggered by diabetes [33]. Increased
deaths were observed in meningitis, miliary TB, EPTB-
DM-HEP and EPTB-DM-HIV. Meningeal TB is particu-
larly challenging to diagnose, since cerebrospinal fluid is
commonly smear and culture negative. Meningitis and a
CD4+ lymphocyte cell counts < 200 have been reported
as risk factor for deaths among EPTB patients by [25].
Meningitis, disseminated disease, patients with EPTB-
HIV and EPTB-DM also have been reported as risk
factors of poor TB outcomes, including increased mor-
tality in other studies [22, 33].
The finding of females, Malays, Indians, urban resi-
dents, patients with EPTB-HIV, EPTB-DM-HIV and
EPTB-HIV-HEP as independent predictors for having
EPTB at the study sites is consistent with studies from
other countries [3, 34–37]. The differences in the
proportion of EPTB by ethnicity are notable. Malay and
Indian patients were generally far more likely to present
with EPTB than others. Differences in the likelihood of
EPTB for racial differences have been observed in
various studies [16, 38]. The mechanism of a racial
difference in infectiousness by MTB is the result of a
complex interaction between the environmental, im-
munologic and genetic factors [38]. However, more stud-
ies among larger number of patients are needed to
further ratify these results. Weak immune system among
DM patients could led them to get infections, including
TB [39]. Patients with DM are identified as risk factors
for PTB in numerous studies [39, 40] but data is scarce
among EPTB patients. One of the remarkable finding of
our study therefore includes patients with DM at greater
risk of EPTB that is in line with the study conducted at
Georgia [33].
Limitations
This study has some limitations for its retrospective
nature. We could not assess whether patients who com-
pleted treatment increased their weight. Beside this,
documentation of diabetes, hepatitis and HIV was likely
to be incomplete. In addition, effect of TB treatment on
CD4+ lymphocyte cell counts was not studied.
Conclusions
With continuous growing trend, EPTB is a grave con-
cern to public health in Malaysia for mainly affecting
nationals. High prevalence of EPTB-DM, EPTB-HIV and
EPTB-HEP as well as their further compound co-mor-
bidities among EPTB in the present study signifies the
fact that these patients are at high risk of developing
EPTB. Active screening measures for patients with co-
morbidities are therefore recommended in patients with
EPTB which could improve the diagnosis and early man-
agement of co-morbidities complications. This strategy
together with educating patients can further increase the
treatment success rate.
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